Sanifit logo portada

A new approach to
calcification disorders

Sanifit logo portada

A new approach to
calcification disorders

 
sanifit

SANIFIT

Sanifit is a biopharmaceutical company focused on treatments for calcification disorders, with SNF472 as lead compound. The company was founded in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Palma (Spain) and San Diego (USA). SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease population undergoing haemodialysis.
After having completed phase Ia studies with healthy volunteers and a phase Ib/IIa study with haemodialysis patients, Sanifit raised a series C funding round of $41.3M (€36.6M). Sanifit is currently running a phase IIb study in ESRD and extending the orphan program in calciphylaxis into phase II/III clinical trials.

ABOUT US

PROJECT SUPPORTED BY

OVERVIEW PIPELINE

THERAPEUTIC PIPELINE

OTC PIPELINE

LATEST NEWS

Your name (required)

Phone (required)

Company

E-mail (required)

Comments

CONTACT

Sanifit

SPAIN
ParcBIT – Ctra Valldemossa km7.4
Building Europa, 2nd floor
07121 Palma

 +34 971 439 925
 info@sanifit.com
USA
4660 La Jolla Village Drive
Suite #500
San Diego, CA 92122